Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain. - Abstract - Europe PMC
interleukin (iL)-17 in the pathogenesis of psoriasis and targets for... | Download Scientific Diagram
Cosentyx (Secukinumab Injection): Uses, Dosage, Side Effects, Interactions, Warning
Ixekizumab (Taltz)
Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities | SpringerLink
Brodalumab: A new way to inhibit IL‐17 in psoriasis - Facheris - 2020 - Dermatologic Therapy - Wiley Online Library
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis | NEJM
Secukinumab Overview - Creative Biolabs
Bimekizumab - an overview | ScienceDirect Topics
Practical Considerations for Treating Psoriasis: Focus on Secukinumab - Practical Dermatology
A Novel Approach to the Treatment of Pembrolizumab-induced Psoriasis Exacerbation: A Case Report - Cureus
Ixekizumab (Taltz)
The Role of the IL-23/IL-17 Pathway in the Pathogenesis of Spondyloarthritis
Psoriatic Arthritis Treatment | COSENTYX® (secukinumab)
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial - ScienceDirect
Latest Therapeutics in Plaque Psoriasis: A Review | ARC Journal of Dermatology
PDF) Secukinumab: IL-17A inhibition to treat psoriatic arthritis
Overview: Secukinumab for Psoriasis | The Dermatologist
Secukinumab: A New Treatment Option for Psoriatic Arthritis | SpringerLink
Targeting of interleukin-17 in the treatment of psoriasis | CCID
What is Cosentyx® (secukinumab)?
Ankylosing Spondylitis Treatment | COSENTYX® (secukinumab)
psoriasis' in Top Selling Monoclonal Antibodies | Scoop.it
FDA APPROVES NEW EVIDENCE THAT COSENTYX® INHIBITS SCALP PSORIASIS - Dizwa
Biologic Therapies for Psoriasis | SpringerLink
Australian Public Assessment Report for Secukinumab (Cosentyx / Zafrez)
